Meridian Bioscience (VIVO) Misses Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 hits record high as rate-hike worries ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Burry doubles down on Nebius short after stock surges 34% on earnings
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Home Depot CEO Ted Decker takes medical leave; two executives step in
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Meridian Bioscience Reports Third Quarter 2016 Operating Results, Declares Regular Cash Dividend, and Updates Fiscal 2016 Guidance
July 28, 2016 8:04 AM EDTGENERAL HIGHLIGHTS
CINCINNATI, July 28, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today:
reported fiscal 2016 third quarter and first nine months net revenues of $50.7 million and $149.1 million, respectively, increases of 5% and 1%, respectively, from the same periods of the prior fiscal year; reported third quarter operating income of $13.7 million, a decrease of 5% from the same period of the prior fiscal year; reported nine months operating... More